Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren safety and efficacy in nonsense mutation cystic fibrosis
NCT02107859Phase 3Terminated
- Sponsor
- PTC Therapeutics, Inc.
- Start
- May 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of ataluren in cystic fibrosis (CF), sponsored by PTC Therapeutics, Inc.. Started May 2014; status: terminated.
02
Drugs
ataluren
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02107859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02107859.